Psychopharmacology: Examine the Emerging Pharmaceutical Treatments for Mental Health Conditions and their Effectiveness Compared to Traditional Medication


  • Sarah Alnaher 7450 Summit Cir, Davison, MI 48423
  • Mohammed Alnaher
  • Moayad Alramahi
  • Abdul Karim Arida



Study background: Mental health poses health, economic, and social burdens worldwide. The existing pharmaceutical interventions against mental diseases produce undesirable adverse effects, creating the need for the exploration of new treatments for more effective medications that do not yield adverse effects. Methods: The present review involved a literature search from electronic databases, including PubMed, ProQuest, Google Scholar, eb of science, and PsycINFO, and was conducted based on the Patient, Intervention, Comparison, Outcomes, and Studies (PICOS), protocol, and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist. Two independent reviewers were assigned study selection and data collection processes that included 16 studies in the review. Results: A review comparing the effectiveness of emerging pharmaceutical interventions against mental illnesses found that the psychedelic class of medications and cannabinoids are emerging effective medications against mental illnesses, including Major Depressive Disorders (MDD), patients with Treatment-Resistant Depression (TRD), and Post-Traumatic Stress Disorder (PSTD). However, the medications produce mild adverse effects.

Keywords - Emerging mental health treatments, Effective medications, traditional medicines, mental health, Psychomarmacology treatment, Psychopharmacology efficacy.


J. Rehm and K. D. Shield, “Global Burden of Disease and the Impact of Mental and Addictive Disorders,” Current Psychiatry Reports, vol. 21, no. 2. 2019. doi: 10.1007/s11920-019-0997-0.

D. Arias, S. Saxena, and S. Verguet, “Quantifying the global burden of mental disorders and their economic value,” EClinicalMedicine, vol. 54, 2022, doi: 10.1016/j.eclinm.2022.101675.

P. C.B. et al., “A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders,” JAMA Psychiatry, vol. 71, no. 5. 2014.

C. B. Pedersen et al., “A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders,” JAMA Psychiatry, vol. 71, no. 5, 2014, doi: 10.1001/jamapsychiatry.2014.16.

Y. Kayiteshonga, V. Sezibera, L. Mugabo, and J. D. Iyamuremye, “Prevalence of mental disorders, associated co-morbidities, health care knowledge and service utilization in Rwanda – towards a blueprint for promoting mental health care services in low- and middle-income countries?,” BMC Public Health, vol. 22, no. 1, 2022, doi: 10.1186/s12889-022-14165-x.

D. C. Agaba, R. Migisha, H. M. Lugobe, G. Katamba, and S. Ashaba, “A 10-Year Risk of Cardiovascular Disease among Patients with Severe Mental Illness at Mbarara Regional Referral Hospital, Southwestern Uganda,” Biomed Res Int, vol. 2020, 2020, doi: 10.1155/2020/2508751.

R. E. Nielsen, J. Banner, and S. E. Jensen, “Cardiovascular disease in patients with severe mental illness,” Nature Reviews Cardiology, vol. 18, no. 2. 2021. doi: 10.1038/s41569-020-00463-7.

N. Yuniarsih, Efek Permainan Kartu Remi Dengan Metode Tepuk Nyamuk Terhadap Fungsi Kognitif dan Interaksi Sosial Pada Lansia di Panti, vol. 9, no. 1. 2019.

Z. H. Teoh et al., “Testosterone therapy and the female-to-male transgender voice: A prospective study,” Endocr Rev, vol. 37, no. 2, 2016.

J. M. Kent, S. J. Mathew, and J. M. Gorman, “Molecular targets in the treatment of anxiety,” Biological Psychiatry, vol. 52, no. 10. 2002. doi: 10.1016/S0006-3223(02)01672-4.

F. Caraci, G. M. Leggio, S. Salomone, and F. Drago, “New drugs in psychiatry: focus on new pharmacological targets [version 1; referees: 3 approved],” F1000Res, vol. 6, no. 0, 2017.

F. Caraci, G. M. Leggio, S. Salomone, and F. Drago, “New drugs in psychiatry: Focus on new pharmacological targets,” F1000Research, vol. 6. 2017. doi: 10.12688/f1000research.10233.1.

M. Nasser et al., “Methodological innovation/Adaptation for systematic reviews for space medicine,” in Proceedings of the International Astronautical Congress, IAC, 2021.

G. M. Tawfik et al., “A step by step guide for conducting a systematic review and meta-analysis with simulation data,” Tropical Medicine and Health, vol. 47, no. 1. 2019. doi: 10.1186/s41182-019-0165-6.

M. Amir-Behghadami and A. Janati, “Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews,” Emergency Medicine Journal, vol. 37, no. 6. 2020. doi: 10.1136/emermed-2020-209567.

L. Jørgensen et al., “Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: Overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews,” Syst Rev, vol. 5, no. 1, 2016, doi: 10.1186/s13643-016-0259-8.

E. Flemyng, K. Dwan, T. H. Moore, M. J. Page, and J. P. Higgins, “Risk of Bias 2 in Cochrane Reviews: a phased approach for the introduction of new methodology,” The Cochrane database of systematic reviews, vol. 10. 2020. doi: 10.1002/14651858.ED000148.

J. J. Yepes-Nuñez, G. Urrútia, M. Romero-García, and S. Alonso-Fernández, “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” Rev Esp Cardiol, vol. 74, no. 9, 2021, doi: 10.1016/j.recesp.2021.06.016.

M. J. Page et al., “The PRISMA 2020 statement: An updated guideline for reporting systematic reviews,” PLoS Medicine, vol. 18, no. 3. 2021. doi: 10.1371/JOURNAL.PMED.1003583.

M. J. Page et al., “The PRISMA 2020 statement: An updated guideline for reporting systematic reviews,” The BMJ, vol. 372. 2021. doi: 10.1136/bmj.n71.

J. G. González-González et al., “Trustworthiness of randomized trials in endocrinology—A systematic survey,” PLoS One, vol. 14, no. 2, 2019, doi: 10.1371/journal.pone.0212360.

O. Barcot et al., “Risk of bias judgments for random sequence generation in Cochrane systematic reviews were frequently not in line with Cochrane Handbook,” BMC Medical Research Methodology, vol. 19, no. 1. 2019. doi: 10.1186/s12874-019-0804-y.

Y. Vali, M. M. G. Leeflang, and P. M. M. Bossuyt, “Application of weighting methods for presenting risk-of-bias assessments in systematic reviews of diagnostic test accuracy studies,” 2021, doi: 10.1186/s13643-021-01744-z.

G. Frampton et al., “Principles and framework for assessing the risk of bias for studies included in comparative quantitative environmental systematic reviews,” Environ Evid, vol. 11, no. 1, 2022, doi: 10.1186/s13750-022-00264-0.

K. Steenland et al., “Risk of Bias Assessments and Evidence Syntheses for Observational Epidemiologic Studies of Environmental and Occupational Exposures: Strengths and Limitations”, doi: 10.1289/EHP6980.

N. Gukasyan et al., “Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up,” Journal of Psychopharmacology, vol. 36, no. 2, 2022, doi: 10.1177/02698811211073759.

A. K. Davis et al., “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial,” JAMA Psychiatry, vol. 78, no. 5, 2021, doi: 10.1001/jamapsychiatry.2020.3285.

R. R. Griffiths, M. W. Johnson, W. A. Richards, B. D. Richards, U. McCann, and R. Jesse, “Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects,” Psychopharmacology (Berl), vol. 218, no. 4, 2011, doi: 10.1007/s00213-011-2358-5.

S. Aaronson, T. Miller, S. Rudow, M. Forbes, A. Shoultz, and T. Suppes, “An Open Label Pilot of The Safety and Efficacy of Comp360 Psilocybin in Patients With Severe Treatment- Resistant Depression,” Neuropsychopharmacology, vol. 47, no. Supplement 1, 2022.

J. Rosenblat and R. McIntyre, “Psilocybin Assisted Therapy for Treatment-Resistant Depression: A Phase II, Randomized, Feasibility Study,” Neuropsychopharmacology, vol. 47, no. Supplement 1, 2022.

G. M. Goodwin et al., “Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life,” J Affect Disord, vol. 327, 2023, doi: 10.1016/j.jad.2023.01.108.

G. M. Goodwin et al., “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression,” New England Journal of Medicine, vol. 387, no. 18, 2022, doi: 10.1056/nejmoa2206443.

R. L. Carhart-Harris et al., “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study,” Lancet Psychiatry, vol. 3, no. 7, 2016, doi: 10.1016/S2215-0366(16)30065-7.

R. L. Carhart-Harris et al., “Psilocybin with psychological support for treatment-resistant depression: six-month follow-up,” Psychopharmacology (Berl), vol. 235, no. 2, 2018, doi: 10.1007/s00213-017-4771-x.

C. Purcell, A. Davis, N. Moolman, and S. M. Taylor, “Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis,” Cannabis and Cannabinoids Research, 2019, doi: 10.1089/can.2018.0020.


E. M. Oliva et al., “Development and applications of the veterans health administration’s stratification tool for opioid risk mitigation (STORM) to improve opioid safety and prevent overdose and suicide,” Psychol Serv, vol. 14, no. 1, pp. 34–49, Feb. 2017, doi: 10.1037/ser0000099.

L. Drost et al., “Efficacy of different varieties of medical cannabis in relieving symptoms in post-traumatic stress disorder (Ptsd) patients,” J Pain Manag, vol. 10, no. 4, 2017.

B. A. Wan et al., “Efficacy of different varieties of medical cannabis in relieving symptoms,” J Pain Manag, vol. 10, no. 4, 2017.

K. Gitau, H. S. Howe, L. Ginsberg, J. Perl, and J. Ailon, “Therapeutic Cannabis Use in Kidney Disease: A Survey of Canadian Nephrologists,” Kidney Med, vol. 4, no. 5, 2022, doi: 10.1016/j.xkme.2022.100453.

S. P. Cahill, S. E. Lunn, P. Diaz, and J. E. Page, “Evaluation of Patient Reported Safety and Efficacy of Cannabis From a Survey of Medical Cannabis Patients in Canada,” Front Public Health, vol. 9, 2021, doi: 10.3389/fpubh.2021.626853.

L. Johansen, P. Liknaitzky, M. Nedeljkovic, L. Mastin-Purcell, and G. Murray, “The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol,” Systematic Reviews, vol. 11, no. 1. 2022. doi: 10.1186/s13643-022-01930-7.

T. Varker, L. Watson, K. Gibson, D. Forbes, and M. L. O’Donnell, “Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin,” Journal of Psychoactive Drugs, vol. 53, no. 1. 2021. doi: 10.1080/02791072.2020.1817639.

J. J. Dawood Hristova and V. Pérez-Jover, “Psychotherapy with Psilocybin for Depression: Systematic Review,” Behavioral Sciences, vol. 13, no. 4. 2023. doi: 10.3390/bs13040297.

J. J. Dawood Hristova and V. Pérez-Jover, “Psychotherapy with Psilocybin for Depression: Systematic Review,” 2023, doi: 10.3390/bs13040297.

L. Luo, L. Du, J. Shen, M. Cen, and N. Dai, “Benefit of small dose antidepressants for functional dyspepsia Experience from a tertiary center in eastern China,” 2019, doi: 10.1097/MD.0000000000017501.

Duffy Larisa et al., “A randomised controlled trial assessing theuse of citalopram, sertraline, fluoxetine andmirtazapine in preventing relapse inprimary care patients who are takinglong-term maintenance antidepressants(ANTLER: ANTidepressants to preventreLapse in dEpRession): study protocol for arandomised controlled trial,” BioMed Central, 2019, doi: 10.1186/s13063-019-3390-8.

G. Agin-Liebes and A. K. Davis, “Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach,” 2022, doi: 10.1007/7854_2021_282.

C. L. Raison et al., “Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial,” JAMA, vol. 330, no. 9, pp. 843–853, 2023, doi: 10.1001/jama.2023.14530.

M. W. Johnson, R. A. Sewell, and R. R. Griffiths, “Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers,” 2011, doi: 10.1016/j.drugalcdep.2011.10.029.

J. Sarris, J. Sinclair, D. Karamacoska, M. Davidson, and J. Firth, “Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review,” BMC Psychiatry, vol. 20, no. 1, 2020, doi: 10.1186/s12888-019-2409-8.

D. Daldegan-Bueno, L. O. Maia, M. Glass, D. Jutras-Aswad, and B. Fischer, “Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies,” Psychopharmacology, vol. 239, no. 5. 2022. doi: 10.1007/s00213-021-05960-2.

M. Scherma, A. Lisa Muntoni, G. Riedel, W. Fratta, and P. Fadda, “Cannabinoids and their therapeutic applications in mental disorders,” Dialogues Clin Neurosci, vol. 22, no. 3, 2020, doi: 10.31887/DCNS.2020.22.3/PFADDA.

E. Engin, “GABAA receptor subtypes and benzodiazepine use, misuse, and abuse,” Frontiers in Psychiatry, vol. 13. 2023. doi: 10.3389/fpsyt.2022.1060949.

S. Robertson, E. E. Peacock, and R. Scott, “Benzodiazepine Use Disorder: Common Questions and Answers,” Am Fam Physician, vol. 108, no. 3, 2023.

H. K. Gill and S. D. Young, “Exploring cannabis use reasons and experiences among mobile cannabis delivery patients,” J Subst Use, vol. 24, no. 1, 2019, doi: 10.1080/14659891.2018.1489012.

S. L. Kvamme, M. M. Pedersen, K. Rømer Thomsen, and B. Thylstrup, “Exploring the use of cannabis as a substitute for prescription drugs in a convenience sample,” Harm Reduct J, vol. 18, no. 1, 2021, doi: 10.1186/s12954-021-00520-5.

I. Jurewicz, “Mental health in young adults and adolescents-supporting general physicians to provide holistic care,” 2015.




How to Cite

Alnaher, S., M. Alnaher, M. Alramahi, and A. K. Arida. “Psychopharmacology: Examine the Emerging Pharmaceutical Treatments for Mental Health Conditions and Their Effectiveness Compared to Traditional Medication”. Journal of Sociology, Psychology & Religious Studies, vol. 5, no. 2, Dec. 2023, pp. 123-42, doi:10.53819/81018102t4237.